Related Articles
Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)
Immunotherapy in malignant peritoneal mesothelioma (Review)
Immunological effect of tyrosine kinase inhibitors on the tumor immune environment in non‑small cell lung cancer (Review)
New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)
Progress in antitumor mechanisms and applications of phenformin (Review)